Cravath’s London Office Moves to 100 Cheapside
July 20, 2018
Cravath represented Royal Bank of Canada in connection with the arrangement of $570 million of senior secured first lien credit facilities and a $225 million senior secured second lien term loan facility made available to MedPlast Holdings, Inc., a designer and producer of precision custom molded thermoplastic, rubber and elastomer components and molds for the healthcare, pharmaceutical and consumer markets. The facilities were used to finance MedPlast’s acquisition of Integer Holdings Corporation’s advanced surgical and orthopedics products business. The transaction closed on July 2, 2018.
The Cravath team included partner Michael S. Goldman, senior attorney Sarah F. Rosen and associates Marc Bode, Stanley I. Onyeador and Joanna Pak on banking matters, and partner Matthew Morreale on environmental matters. Summer associate Kelly N. King also worked on this matter.
Deals & Cases
February 13, 2025
On February 4, 2025, Marlin Equity Partners, a leading global investment firm, announced its acquisition of EIDO Healthcare, a leading provider of digital consent and patient information solutions. EIDO Healthcare will be combined with Radar Healthcare, an existing Marlin Equity Partners portfolio company and a provider of risk, quality, and compliance software for the healthcare and social care sectors. Cravath represented Marlin Equity Partners in the committed debt financing in connection with the transaction.
Deals & Cases
October 02, 2024
On September 25, 2024, Investcorp a leading global alternative investment firm, announced its acquisition of Stowe Family Law Holdings Limited, the largest specialist family law firm in the United Kingdom. Cravath represented Investcorp in the committed debt financing in connection with the transaction.
Deals & Cases
February 05, 2024
Cravath represented Artivion, Inc. in connection with $350 million of credit facilities obtained from Ares Management Credit funds to comprehensively address its debt maturities. Artivion is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with aortic diseases. The facilities consisted of a $190 million secured term loan facility, a $100 million secured delayed draw term loan facility and a $60 million secured revolving credit facility. The transaction closed on January 18, 2024.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.